Company intelligence / Profile preview

ECI Group

Cambridge, Massachusetts, United Statesecigroups.com ↗

Ownership: Private
Development stage: Other

Overview

ECI Therapeutics develops biologic products using a proprietary platform that combines human platelet-rich plasma-derived growth factors with chitosan or hyaluronic acid excipients. The lead indication, neurotrophic keratitis, has received orphan drug designation from the FDA. The company aims to address significant unmet needs in ophthalmology—especially rare corneal diseases—and wound care by providing safer, more effective alternatives to current treatments. Clinical results are pending; first Phase II trial anticipated in 2026.

Therapeutic areas: DermatologyOphthalmology
Modalities: Biologic (platelet-rich plasma-derived growth factors)Recombinant protein (growth factor-based therapies)Chitosan/hyaluronic acid excipient platform
Industry: Biotech

Beyond the preview

Go deeper on ECI Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ECI Group.

Explore the full profile